SELLAS Life Sciences Group, Inc.
Close on Oct 19, 2026
- Market cap
- $1.98B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | During market hours | – | $-0.05 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | During market hours | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 19, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | During market hours | – | $-0.06 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | During market hours | – | $-0.07 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | During market hours | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 20, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | During market hours | – | $-0.13 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | During market hours | – | $-0.21 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | During market hours | – | – | – |
Press releases
Announcements SELLAS Life Sciences filed with the SEC
SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds
Material agreement · Other events · EX-99.1 to Form 8-K
Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
SELLAS Life Sciences Group Announces $25 Million
Material agreement · Other events · EX-99.1 to Form 8-K
Life Sciences Announces Positive Outcome of Interim Analysis for its
Regulation FD disclosure · EX-99.1 to Form 8-K
SELLAS Life Sciences Triggers Interim Analysis
Regulation FD disclosure · EX-99.1 to Form 8-K
C O R P O R A T E P A R T I
Regulation FD disclosure · EX-99.2 to Form 8-K
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
SELLAS Life Sciences Announces $21.0 Million
Material agreement · Other events · EX-99.1 to Form 8-K
SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
SELLAS Life Sciences Group Announces $20 Million Registered
Material agreement · Other events · EX-99.1 to Form 8-K
SELLAS Announces Executive Leadership Reorganization
Executive or director change · Other events · EX-99.1 to Form 8-K
Announces Pricing of $9.0 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
SELLAS Life Sciences Announces $4 Million Registered
Material agreement · Other events · EX-99.1 to Form 8-K
SELLAS Life Sciences Receives Fast Track Designation from FDA for SLS009 for Treatment of Relapsed/Refractory
Material agreement · Other events · EX-99.2 to Form 8-K
SELLAS Announces Positive Initial Topline Phase
Other events · EX-99.1 to Form 8-K
SELLAS Life Sciences Provides Update on Phase
Other events · EX-99.1 to Form 8-K
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
O R P O R A T E P A R T I C I P A N T S
Regulation FD disclosure · EX-99.1 to Form 8-K
SELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
this Exhibit 99.1 for the purpose of incorporating the information set forth herein by reference into the registration statement on Form S-3 (File No. 333-255318) that was filed
Material agreement · Other events · EX-99.1 to Form 8-K
SELLAS Life Sciences Announces Pricing of $20.0
Material agreement · Other events · EX-99.2 to Form 8-K
SELLAS Announces Positive Phase 1 Data with
Other events · EX-99.1 to Form 8-K
C O R P O R A T E P A R T I
Regulation FD disclosure · EX-99.1 to Form 8-K
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2022 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
SELLAS Life Sciences Announces Update on Phase 3 REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia
Results of operations · Other events · EX-99.2 to Form 8-K
Investor Symposium on Galinpepimut - S September 15, 2022 NASDAQ: SLS
Regulation FD disclosure · EX-99.1 to Form 8-K
C O R P O R A T E P A R T I
Regulation FD disclosure · EX-99.2 to Form 8-K
SELLAS Life Sciences’ Announces Election
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K